merged_china-pharma-drugs.txt
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article does not mention Dr. Lu Changlin citing a specific foreign pharmaceutical company's blood pressure medication.</other>

<question_number>2</question_number>
<answer>N/A</answer>
<other>The article does not provide information on the number of doctors reporting adverse reactions to domestically produced anesthetics.</other>

<question_number>3</question_number>
<answer>N/A</answer>
<other>The article does not mention a specific percentage reduction in efficacy found by Dr. Xia Zhimin.</other>

<question_number>4</question_number>
<answer>N/A</answer>
<other>The article does not provide a regional breakdown of cost savings by province.</other>

<question_number>5</question_number>
<answer>N/A</answer>
<other>The article does not provide the total monetary value of foreign-branded drugs excluded from the national health insurance list.</other>

<question_number>6</question_number>
<answer>N/A</answer>
<other>The article does not provide information on the number of patients who experienced complications from the antibiotics mentioned by Dr. Zheng Minhua.</other>

<question_number>7</question_number>
<answer>N/A</answer>
<other>The article mentions that doctors and Communist Party members submitted proposals to change the procurement system, but it does not detail the specific regulatory changes proposed before the investigation.</other>

<question_number>8</question_number>
<answer>N/A</answer>
<other>The article does not provide Dr. Li Xiang's clinical observations on the failure rate of domestic generic medications compared to imported counterparts.</other>

<question_number>9</question_number>
<answer>N/A</answer>
<other>The article does not mention the National Medical Products Administration citing specific international pharmaceutical quality standards.</other>

<question_number>10</question_number>
<answer>N/A</answer>
<other>The article does not provide information on the percentage of private clinics that reported maintaining stocks of foreign-branded medications.</other>

<question_number>11</question_number>
<answer>China's National Healthcare Security Administration</answer>
<other>The article states that China's National Healthcare Security Administration dispatched officials to Shanghai to speak to doctors and examine clinical data.</other>

<question_number>12</question_number>
<answer>Dr. Xia Zhimin</answer>
<other>The article mentions Dr. Xia Zhimin comparing clinical trial reports and suggesting that the trial data for domestic generics might have been duplicated.</other>

<question_number>13</question_number>
<answer>Dr. Zheng Minhua, the director of surgery at Ruijin Hospital</answer>
<other>The article cites Dr. Zheng Minhua expressing worry about the quality of low-price drugs.</other>

<question_number>14</question_number>
<answer>volume-based procurement</answer>
<other>The article mentions that the volume-based procurement mechanism was criticized for limiting access to imported drugs.</other>

<question_number>15</question_number>
<answer>a former editor at a leading online health platform (Dr. Xia Zhimin)</answer>
<other>The article mentions a former editor at a leading online health platform accusing domestic drug manufacturers of fraud, and Dr. Xia Zhimin is identified as the former deputy editor in chief of Ding Xiang Doctor.</other>

<question_number>16</question_number>
<answer>the policy put in place in 2018, known as volume-based procurement</answer>
<other>The article states that the policy put in place in 2018 has led to a surge in domestic generics.</other>

<question_number>17</question_number>
<answer>Dr. Lu Changlin</answer>
<other>The article mentions Dr. Lu Changlin proposing that patients and doctors should not be compelled to use drugs solely from the government procurement list.</other>

<question_number>18</question_number>
<answer>China</answer>
<other>The article discusses China's government and its cost-cutting campaign and centralized bidding system.</other>

<question_number>19</question_number>
<answer>private clinics</answer>
<other>The article notes that patients who use private clinics have easier access to a wider choice of medication, including foreign brands.</other>

<question_number>20</question_number>
<answer>Dr. Xia Zhimin</answer>
<other>The article mentions Dr. Xia Zhimin posting on social media about the duplicated clinical trial numbers for domestic generics.</other>